Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 1 for:    NCT00552305
Previous Study | Return to List | Next Study

To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

This study has been completed.
Information provided by (Responsible Party):
UCB Pharma Identifier:
First received: October 30, 2007
Last updated: September 19, 2014
Last verified: September 2011
The purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy.

Condition Intervention Phase
Partial Epilepsies
Drug: lacosamide
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label Extension Trial to Determine Tolerability and Efficacy of Long-term Oral SPM 927 as Adjunctive Therapy in Patients With Partial Seizures

Resource links provided by NLM:

Further study details as provided by UCB Pharma:

Primary Outcome Measures:
  • Number of Subjects Reporting at Least 1 Treat-Emergent Adverse Event (TEAE) During the Treatment Period (up to 8 Years) [ Time Frame: During the Treatment Period (up to 8 years) ] [ Designated as safety issue: No ]
    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

  • Number of Subjects Prematurely Discontinuing Due to a Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (up to 8 Years) [ Time Frame: During the Treatment Period (up to 8 years) ] [ Designated as safety issue: No ]
    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

  • Number of Subjects Reporting at Least 1 Serious Adverse Event (SAE) During the Treatment Period (up to 8 Years) [ Time Frame: During the Treatment Period (up to 8 years) ] [ Designated as safety issue: No ]
    A serious adverse event is any untoward medical occurrences in a subject administered study treatment, whether or not the event is related to treatment, with at least one of the follow outcomes: death, life-threatening, initial inpatient hospitalization or prolongation of hospitalization, significant or persistent disability/incapacity, congenital anomaly/birth defect, or an important medical event that may jeopardize the subject and require a medical/surgical intervention.

Secondary Outcome Measures:
  • Median Percentage Change From Baseline in 28-day Seizure Frequency During the Treatment Period (up to 8 Years) [ Time Frame: Baseline, End of Treatment Period (up to 8 years) ] [ Designated as safety issue: No ]

    Median percentage change is the median value with respect to the percent change from Baseline across the population of subjects. Percentage change is calculated as 100 times the difference of the seizure frequency for the treatment period and the Baseline seizure frequency divided by the baseline seizure frequency.

    Negative changes from Baseline indicate an improvement (i.e., a reduction) in 28-day seizure frequency.

  • Percentage of at Least 50% Responders During the Treatment Period (up to 8 Years) [ Time Frame: Treatment Period (up to 8 years) ] [ Designated as safety issue: No ]
    At least 50 percent response is based on the percentage reduction in 28-day seizure frequency during the Treatment Period of the open-label extension relative to the Baseline Phase of the prior study. This endpoint reflects the percentage of subjects with at least 50% reduction (ie, at least 50% change) in 28-day partial onset seizure frequency

Enrollment: 370
Study Start Date: August 2001
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lacosamide
50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing
Drug: lacosamide
50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
Other Name: Vimpat


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completion of parent clinical trial for treatment of partial seizures.

Exclusion Criteria:

  • Receiving any study drug or experimental device other than lacosamide.
  • Meets withdrawal criteria for parent trial or experiencing ongoing serious adverse event.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00552305

  Hide Study Locations
United States, Alabama
Birmingham, Alabama, United States
Huntsville, Alabama, United States
United States, Arizona
Phoenix, Arizona, United States
Tucson, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
Los Angeles, California, United States
United States, Colorado
Englewood, Colorado, United States
United States, Florida
Gainesville, Florida, United States
Hollywood, Florida, United States
Miami, Florida, United States
Ponte Verda Beach, Florida, United States
United States, Illinois
Chicago, Illinois, United States
Springfield, Illinois, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Iowa
Iowa City, Iowa, United States
United States, Kansas
Wichita, Kansas, United States
United States, Kentucky
Crestview Hills, Kentucky, United States
Lexington, Kentucky, United States
United States, Maryland
Baltimore, Maryland, United States
Frederick, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Michigan
Ann Arbor, Michigan, United States
Detroit, Michigan, United States
United States, Minnesota
St Paul, Minnesota, United States
United States, Missouri
Chesterfield, Missouri, United States
St Louis, Missouri, United States
United States, New Jersey
Somerset, New Jersey, United States
United States, New York
New York, New York, United States
United States, North Carolina
Durham, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
United States, Pennsylvania
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
United States, Tennessee
Nashville, Tennessee, United States
United States, Texas
Dallas, Texas, United States
Irving, Texas, United States
Lubbock, Texas, United States
Wichita Falls, Texas, United States
United States, Vermont
Bennington, Vermont, United States
United States, Virginia
Charlottesville, Virginia, United States
United States, Wisconsin
Marshfield, Wisconsin, United States
Milwaukee, Wisconsin, United States
Bonn, Germany
Erlangen, Germany
Kehl Kork, Germany
Schwalmstedt-Treysa, Germany
Budapest, Hungary
Zalaegerszeg, Hungary
Kaunas, Lithuania
Vilnius, Lithuania
Poznan, Poland
Goteborg, Sweden
Stockholm, Sweden
Bern/Biel, Switzerland
Zurich, Switzerland
United Kingdom
Bucks/London, United Kingdom
Glasgow, United Kingdom
Liverpool, United Kingdom
Sponsors and Collaborators
UCB Pharma
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: UCB Pharma Identifier: NCT00552305     History of Changes
Other Study ID Numbers: SP0615 
Study First Received: October 30, 2007
Results First Received: February 23, 2011
Last Updated: September 19, 2014
Health Authority: United States: Food and Drug Administration
Germany: Federal Institute for Drugs and Medical Devices
Hungary: National Institute of Pharmacy
Lithuania: State Medicine Control Agency - Ministry of Health
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Sweden: Medical Products Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Anticonvulsants processed this record on December 09, 2016